Foundation Medicine, Bristol Myers Squibb Expand CDx Partnership to Investigational Cancer Drug
The companies are working to establish FoundationOne CDx as a companion diagnostic for BMS's investigational tyrosine kinase inhibitor repotrectinib.
InnoCare Expands Phase I/II Trial ICP-723 to Include Adolescent Patients
Positive results from an ongoing trial of the TRK inhibitor in adults have encouraged the company to open up enrollment to adolescents with plans to later involve younger children.
Lantern Pharma Gets FDA Nod to Begin Phase II Trial of LP-300 in Biomarker-Defined NSCLC
The trial will enroll 90 never-smoker patients with advanced NSCLC harboring alterations in MET exon 14, ALK, EGFR, or NTRK.
MD Anderson, Turning Point Therapeutics Partner to Study Repotrectinib, Elzovantinib
The research will include preclinical and clinical studies of ROS1/NTRK inhibitor repotrectinib and MET inhibitor elzovantinib in several tumor types.
Illumina Adds CDx Indication to European TruSight Oncology Test for NTRK Gene Fusion Detection
The CDx pan-cancer indication will allow the identification of patients with NTRK gene fusions who may benefit from therapy with Bayer's Vitrakvi (larotrectinib).